腹主动脉瘤腔内修复术使用GORE® EXCLUDER®装置的五年结果:来自Gore全球血管腔内主动脉治疗注册研究(GREAT)的见解
研究基于GREAT注册研究纳入3216例接受GORE EXCLUDER装置行肾下腹主动脉瘤腔内修复术的患者,随访5年时60%合格参与者有数据。5年免于主动脉相关死亡率为98.8%,总生存率71.2%,装置相关再干预率7.2%,严重内漏率6.8%,瘤囊回缩率58.1%。结论支持该装置5年内的耐久性。
要点
- 5年免于主动脉相关死亡率98.8%,总生存率71.2%。
- 装置相关再干预率7.2%,严重内漏率6.8%。
- 5年瘤囊回缩率58.1%,瘤囊稳定/无增长83.6%。
核心结论
- 本研究支持GORE EXCLUDER装置5年内的耐久性,移植物质完整性受损发生率极低,主动脉/装置相关再干预率低。
- 该装置疗效突出,表现为主动脉相关死亡率低以及5年内瘤囊回缩/稳定直径比例高。
研究设计与样本
- 基于Gore全球血管腔内主动脉治疗注册研究(GREAT)的注册研究。
- 纳入所有接受GORE EXCLUDER装置行肾下腹主动脉瘤修复术的患者,共3216例。
- 收集队列基线特征和人口学信息,终点包括死亡、严重内漏、瘤囊直径、内移植物完整性、术后主动脉破裂、装置相关再干预、开放手术转换、移植物取出和主要不良心血管事件。
主要发现
- 5年随访时60%的合格参与者有数据。
- 免于主动脉相关死亡率为98.8%,总生存率为71.2%。
- 术后主要不良心血管事件发生于49例(1.5%)患者。
- 5年内装置相关干预率为7.2%,总体严重内漏率为6.8%。
- 需要开放转换/翻修的患者不足1%,装置放置后主动脉破裂发生于15例(0.5%)患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The early postoperative benefits of endovascular aneurysm repair (EVAR) have been well established but questions remain regarding its durability at mid-term and long-term time points. Long-term results in real-world use of EVAR outside of randomized trial data are limited. This study used the Global Registry for Endovascular Aortic Treatment registry to explore the 5-year outcomes with the GORE EXCLUDER device in real-world clinical circumstances. METHODS: All patients within the Global Registry for Endovascular Aortic Treatment registry who underwent an infrarenal abdominal aortic aneurysm repair with the GORE EXCLUDER device were included in this study. Baseline characteristics and demographic information of the cohort were collected. End points included mortality (all-cause and aneurysm-related), serious endoleaks, aneurysm sac diameter, endograft integrity (fracture, compression, migration), post-EVAR aortic rupture, device-related reintervention, conversion to open repair, graft explantation, and major adverse cardiovascular events. RESULTS: A total of 3,216 patients were included in this analysis. The cohort reflected a significantly comorbid population with 46% of patients reaching a Charlson Comorbidity Index score of ≥5. Follow-up at 5 years was 60% of eligible participants. The freedom from aortic-related mortality was at 98.8% and overall survival was 71.2%. Postoperative major adverse cardiovascular events occurred in 49 (1.5%) patients. Device-related intervention through 5 years was 7.2% and the overall serious endoleak rate was 6.8%. Less than 1% of patients required an open conversion/revision and aortic rupture following device placement occurred in 15 (0.5%) patients. Aneurysm sac regression was achieved in 58.1% of patients at 5 years, and stability/absence of growth was observed in 83.6% at 5 years. CONCLUSIONS: This study supports the durability of the GORE EXCLUDER device through 5 years with negligible incidence of graft integrity compromise and low aortic/device-related reintervention rates. Furthermore, the efficacy of the device is highlighted with low aortic-related mortality and high sac regression/stability diameter through 5 years.
引用
- Long C, Katsargyris A, Milner R, et al. Five-Year Results for Abdominal Aortic Aneurysm Repair with the GORE® EXCLUDER® Device: Insights from the Gore Global Registry for Endovascular Aortic Treatment (GREAT). Ann Vasc Surg. 2024. PMID: 38815908. doi:10.1016/j.avsg.2024.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。